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Results: The study included 65 women and 35 men, with 77%
being White, 18% African American, 2% Asian, and 3% Other.
Mean age of the subjects was 63.5 years (± 8.7). 54% of the
subjects reported daily vitamin D supplementation, with 31%
taking <400 IU vitamin D and 23% taking ≥400 IU. Mean base-
line serum (OH)D level was 31.6 (± 12.6) ng/ml, with 47% of
subjects found to be vitamin D deﬁcient. Many subjects were
vitamin D deﬁcient in spite of supplementation (42% who took
≤400 IU vitamin D, and 30% of those taking >400 IU vitamin
D). However, after adjustment for age, gender, race, BMI, edu-
cation, and month of blood draw, vitamin D supplementation was
associated with decreased risk of vitamin D deﬁciency (subjects
taking 1-400 IU vitamin D vs. no-taking, OR = 0.51, 95% CI,
0.16-1.63; subjects taking >400 IU vitamin D vs. no-taking, OR
= 0.26, 95% CI, 0.07-1.04), p trend = 0.047. In these models,
lower vitamin D levels were inversely associated with education
(college graduate or above vs. under, OR = 0.28, 95% CI, 0.09-
0.84), and positively associated with African-American race (OR
= 4.10, 95% CI, 0.94-18.0).
Conclusions: Many individuals with knee OA are vitamin D
deﬁcient in spite of daily vitamin D supplementation. Current
recommendation with respect to vitamin D supplementation may
require reconsideration for individuals with OA.
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COMPARATOR TRIAL
T.J. Schnitzer1, I.D. Dattani2, B. Seriolo3, H. Schneider4,
S. Yu5, L. Tseng5, R. Rebuli6
1Northwestern Center for Clinical Research, Chicago, IL; 2Prairie
Clinical Research Group, Saskatoon, SK, Canada; 3Ricercatore
Confermato, Clinica Reumatologica, Università di Genova,
Genova, Italy; 4Facharzt für Orthopädie/Sportmedizin, Bad
Nauheim, Germany; 5Novartis Pharmaceuticals Corporation,
East Hanover, NJ; 6Novartis Pharma AG, Basel, Switzerland
Purpose: Hip osteoarthritis (OA) is a debilitating musculoskeletal
disorder, characterized by chronic pain, affecting health related
quality of life. Lumiracoxib is a selective COX-2 inhibitor that
provides an alternative to traditional NSAIDs for the treatment of
OA. The present study was designed to demonstrate the efﬁcacy
and safety of lumiracoxib (100 mg od) compared with placebo in
patients with primary hip OA. Celecoxib (200 mg od) was used
as the positive control.
Methods: The primary efﬁcacy variables included patient’s global
assessment of disease activity (0-100 mm VAS), WOMAC™ 3.1
LK pain sub-scale score and WOMAC™ difﬁculty performing
daily activities (DPDA) sub-scale score (at Week 13). Prespec-
iﬁed secondary efﬁcacy variables included response to treat-
ment according to Osteoarthritis Research Society International
(OARSI) criteria at Weeks 4, 8 and 13; and minimal clinically im-
portant improvement (MCII) for hip OA pain by visit. The efﬁcacy
in the subgroup of patients ≥65 years was also prespeciﬁed to
be analyzed for these primary outcomes.
Results: A total of 1262 primary hip OA patients aged ≥40
years (490 were ≥65 years of age) were randomized to receive
lumiracoxib 100 mg od (n=427), celecoxib 200 mg od (n=419),
or placebo (n=416) over a period of 13 weeks. Lumiracoxib was
signiﬁcantly superior to placebo in all primary efﬁcacy variables
and provided similar pain relief compared with celecoxib at 13
weeks (in both overall population and ≥65 years sub group, Table
1). The treatment response in <65 age group was also similar
to the overall population and statistically signiﬁcant compared to
placebo.
Table 1. Efﬁcacy of lumiracoxib versus placebo for primary outcomes (estimated
difference after 13 weeks)
Lumiracoxib vs Placebo
LSM difference (95% CI)
Overall Population ≥65 years
Patient’s global assessment of
disease activity (VAS, mm) -8.59 (-11.84, -5.33)* -9.60 (-14.94, -4.25)*
WOMAC™ pain (0-20) scores -1.12 (-1.63, -0.60)* -1.63 (-2.48, -0.78)*
WOMAC™ DPDA (0-68) scores -3.58 (-5.24, -1.91)* -4.16 (-6.90, -1.42)**
*p<0.001, **p=0.003.
Similar results for all primary endpoints were observed for cele-
coxib vs placebo in the overall population and patients ≥65 years.
A greater proportion of patients in the lumiracoxib group (63.0%,
67.0%, 65.8%) had a treatment response according to OARSI
criteria at Weeks 4, 8 and 13 compared with placebo (45.4%,
50.0%, 53.6%) and the response was similar to that in the cele-
coxib group (63.7%, 67.5%, 67.8%). Lumiracoxib and celecoxib
were statistically superior to placebo in the achievement of MCII
for target hip OA pain after 4 weeks (p≤0.001; p=0.004), 8 weeks
(both p≤0.001), and 13 weeks (both p≤0.001) of treatment. The
incidence of adverse events in the lumiracoxib, celecoxib and
placebo groups was 56.4%, 53% and 47.6%, respectively. The
overall percentage of serious adverse events (SAEs) was 1.9%,
1.0% and 2.2% in the respective groups. There were no fatal
SAEs in the lumiracoxib and placebo groups. Two deaths oc-
curred in the celecoxib group that were not suspected to be
study drug related. Two patients (0.5%) had AST and/or ALT
elevations >3 x ULN in the placebo group versus no elevations
in the active treatment groups.
Conclusions: Lumiracoxib 100 mg od and celecoxib 200 mg od
were well tolerated and provided similar pain relief and improve-
ment in functional status in patients with primary hip OA. Efﬁcacy
was maintained in patients ≥65 years.
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Johns Hopkins University, Baltimore, MD
Purpose: The placebo effect is inherent to all treatments. Phar-
macotherapy trials assess whether speciﬁc effects of an agent
are signiﬁcantly greater than non-speciﬁc inﬂuences (placebo) on
treatment outcomes. In OA trials, rates of placebo response often
approach or exceed 50%. Despite this, very little is known about
sociodemographic or clinical predictors of placebo response.
Methods: Data were drawn from placebo arm of North Amer-
ican patients in a large clinical trial designed to evaluate the
clinical effects of risedronate on knee OA (KOSTAR). OARSI
pain criteria (20% and 50% decrease in WOMAC pain) were
used to classify participants at 6 months as placebo respon-
ders. We examined whether placebo response was associated
with baseline demographic, clinical, and radiographic parameters
including: age, gender, race, BMI, work status, WOMAC (pain,
stiffness, function), patient global assessment, OA at other sites,
NSAID, analgesic and glucosamine use, joint space width (JSW)
and osteophyte grade.
Results: Of 311 OA patients who started the trial, 269 (86%)
completed the 6 month evaluations. Subjects were mostly female
(60%) and white (84%) with a mean (± SD) age of 60.4 ±
8.9, BMI of 30.2 ± 5.0, OARSI osteophyte grade of 1.6 ±
0.6 and baseline pain (WOMAC) of 35.1 ± 21.5. Nearly half
(49%) reported a 20% decrease in pain while 29% reported a
50% decrease, with no between-group differences by gender or
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obesity status (yes/no). Patients with moderate pain at baseline
had a 1.6 fold greater odds (95% CI 1.0-2.6) of a 20% placebo
response and 1.7 fold (95% CI 1.0-2.9) than those with either
low (≤ 30) or high (≥70) levels of baseline pain.
A 20% reduction in pain was associated with higher baseline
pain (38.7 ± 21.6 vs. 31.8 ± 20.9, p = 0.008), and a trend
(p = 0.08) toward greater joint space width (3.02 ± 0.60 vs.
2.90 ± 0.57). No between-group differences were evident in
use of pain medication or glucosamine, though 20% placebo
responders were less likely to use analgesics 75% or more of
the time during the trial (OR = 0.43; 95% CI 0.26-0.73). No
differences were observed between placebo 50% responders
and non-responders in sociodemographic or joint characteristics.
Patients with a 50% decrease in pain were less likely to report
use of pain medications at baseline (OR = 0.41; 95% CI 0.22-
0.76), chronically (OR = 0.57; 95% CI 0.33 - 0.97) or during the
trial (OR = 0.37; 95% CI = 0.22-0.65). 50% responders were
also less likely to have OA in 1+ other sites (OR = 0.30; 95%
CI = 0.11-0.79) with a trend toward a greater odds of using
glucosamine (OR = 1.6; 95% CI 0.92 - 2.8).
Conclusions: As in other large OA trials, nearly half of per-
sons receiving placebo had clinically detectable and 29% had
clinically meaningful improvements in pain. Placebo responders
were more likely to report moderate pain at baseline and less
likely to use pain medications. Overall, there do not appear
to be sociodemographic or disease-related characteristics that
can reliably predict placebo response. However, OA trials often
selectively target individuals with moderate pain and less medi-
cation use - factors that may increase the prevalence of placebo
responders.
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DISTRIBUTION OF JOINT INVOLVEMENT IN WOMEN
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TO OUTCOMES MEASURES
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Diakonhjemmet Hospital, Oslo, Norway
Purpose: It is unclear whether involvement of certain joint areas
have a particular impact on the patients pain and function.
The objective of the present study was to investigate the asso-
ciation between clinically assessed ﬁnger joint involvement and
outcome measures.
Methods:One hundred and ninety female HOA patients between
50 and 70 years of age with a mean (SD) age of 61.6 (5.6) years
completed a comprehensive clinical examination including as-
sessment of joint status and fulﬁllment of several questionnaires,
among them AUSCAN, AIMS2 and VAS scale for pain. Grip
strength was examined as a performance based assessment.
Associations were examined by Pearson correlation coefﬁcients.
Levels of health status were compared across areas of joint
involvement by Student T-test.
Results: The mean (SD) number of joints showing bony enlarge-
ment was 0.39 (0.66) for CMC joints, 2.86 (2.91) for PIP joints
and 4.47 (2.56) for DIP joints.The number of involved PIP joints
was signiﬁcantly correlated to AUSCAN pain (r=0.21, p=0.005)
and stiffness (r=0.21,p=0.006), and the number of DIP joints
showed a signiﬁcant correlation to grip strength bilaterally (r=-
0.19, p=0.01 right hand and -1.55, p=0.04 left hand).Health status
levels in patients with and without presence of joint involvement
are shown in table. Only a small number of differences were
statistically signiﬁcant (Table).
Conclusions: Worse health status was associated with an in-
creased number of joints involved, but the ﬁndings did not sup-
port the assumption that involvement of speciﬁc joint areas could
have any major impact on outcome measures.
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PROGRESSION OF OSTEOARTHRITIS IN THE LOWER
EXTREMITIES: A CLINICAL AND RADIOLOGICAL
FOLLOW-UP STUDY.
M. Kloppenbur, S. Botha-Scheepers, I. Watt, F.R. Rosendaal,
F.C. Breedveld
Leiden University Medical Center, Leiden, The Netherlands
Purpose: Although many people suffer from pain and disability
due to osteoarthritis (OA) in the lower extremities, knowledge
about progression of OA and how to assess progression of OA
is limited. The purpose of the present study is to investigate
currently available outcome measures, that assess clinical as
well as structural and social aspects of OA, to evaluate their
responsiveness in a series of patients with OA in the lower
extremities over a two year follow-up.
Methods: Participants of the GARP study (Genetics, ARthro-
sis and Progression) - a 2-year follow-up study in patients with
familial OA at multiple sites- with symptomatic knee or hip OA
were included in the present study. Knee or hip OA were de-
ﬁned following the American College of Rheumatology criteria
for knee and hip OA, requiring both symptoms on most days of
the preceding month in addition to radiographic abnormalities.
Standardized knee and hip radiographs were made at baseline
and follow-up. Medial and lateral tibiofemoral joints and hips
were scored by 2 readers in consensus for change in joint space
narrowing (JSN) using the OARSI atlas. Readers scored the
radiographs paired and blind for sequence. Radiographic total
scores ranged from 0-18. Smallest detectable difference over 2
years was one point. Pain intensity in knees and hips upon pas-
sive movement (a modiﬁcation of the Doyle index) was graded
during physical examination on a 4-point scale for intensity (max-
imal total score 0-16). Self-reported pain and physical function
for the lower extremities, including both knees and hips, were
evaluated by Western Ontario and McMasters Universities os-
teoarthritis index (WOMAC) in its visual analogue scale format;
scores ranged from 0-100. Social functioning was assessed with
the social functioning score (range 0-100; higher score indicate
better social functioning) of the RAND 36-item Health Survey.
Standardized response means (SRMs) were calculated to evalu-
ate responsiveness.
Results: Of the 127 eligible patients for the present study 115
(91%) patients (mean age 60 years, 80% female) completed
the 2 year follow-up. Symptomatic hip OA and knee OA were
present in 76 and 53 patients respectively and 14 patients had
a combination of both. 23% of the patients had an increase
of at least one point in JSN total scores. An increase in pain
intensity total scores at physical examination was present in
46% of patients, whereas a decrease was observed in 19% of
the patients. Statistically signiﬁcant deterioration in JSN (mean
change 0.3 (95% CI 0.2-0.4)) and pain intensity total score (0.9
(0.5-1.3) were seen in the whole patient population. SRMs were
0.43 and 0.41, respectively. WOMAC pain and function scores
showed small non-signiﬁcant deterioration. SRMs were 0.15 and
0.18 respectively. No change was seen in social functioning
scores (SRM 0.01).
Conclusions: The current study suggests that instruments mea-
suring structural abnormalities and clinical symptoms during
physical examination are more responsive to change over 2
years in patients with OA in the lower extremities than self-
reported measurements of pain, disability and social functioning
in OA. Whether these ﬁndings reﬂect the course of the OA pro-
cess in the patients or are associated on the type and quality
of the instruments has to be investigated. Further validation and
development of instruments to evaluate OA progression is war-
ranted to improve the measurement of disease outcome in OA
of the lower extremities.
